7 December 2022 - - US-based pharmaceutical company Bryn Pharma LLC has appointed Sandy Loreaux and William D. Humphries to its board of directors, the company said.

Loreaux and Humphries join Anne Whitaker and Lisa Licht to round out the senior directors focused on commercialization of UTULY.

Loreaux has over 25 years of experience in the pharmaceutical industry. She currently leads Covis Pharma's US Operations in her role as US president.

Sandy joined Covis in November 2021 after previously serving as senior vice president and general manager, US Critical Care for Mallinckrodt Pharmaceuticals.

She has led multiple market access initiatives in her roles as SVP, Head of Market Access at Mallinckrodt Pharmaceuticals and SVP, Head of Market Access, and Commercial Operations at Bausch Health.

Loreaux spent the first 19 years of her career at Sanofi and its legacy companies in various roles of increasing responsibility across medical affairs, sales, marketing and market access.

Loreaux is a pharmacist by training and has a degree from Temple University School of Pharmacy in Philadelphia.

As a mother of children who were diagnosed with life-threatening food allergies as infants, Loreaux brings a personal passion and commitment to bringing epinephrine delivery alternatives to market.

Humphries has more than 30 years of experience building and leading commercial-stage pharmaceutical organizations.

He is currently the chief executive officer of Isosceles Pharmaceuticals, a position he has held since May 2021.

Previously, Humphries served as president of Ortho Dermatologics, a Bausch Health company. Before joining Ortho Dermatologics, he served as president and chief executive officer of the North American business of Merz, an affiliate of Merz Pharma Group, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics Inc., and Merz Pharma Canada Ltd.

Before joining Merz, he served in several leadership positions with Stiefel Laboratories, including Chief Commercial Officer and president, where he spearheaded two significant acquisitions and led the global integration of Stiefel into GlaxoSmithKline.

Earlier in his career, Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, concluding as vice president of its US skincare business.

Bryn Pharma, established in 2017, is a privately held pharmaceutical company.

Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients.